[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
3. Khan F, Vessal S, McKimm E, D'Souza R: Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma. BMJ Case Rep; 2010;2010
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous gastrosplenic fistula secondary to primary splenic lymphoma.
  • A gastrosplenic fistula is a rare complication of gastric and splenic lymphomas which can occur spontaneously or secondary to chemotherapy.
  • We report a case of a spontaneous gastrosplenic fistula secondary to a diffuse splenic large B cell lymphoma in a previously well 43-year-old patient.
  • CT imaging demonstrated the fistula, which was subsequently managed with chemotherapy.
  • [MeSH-major] Fistula / etiology. Fistula / radiography. Gastric Fistula / etiology. Gastric Fistula / radiography. Image Interpretation, Computer-Assisted. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / radiography. Multidetector Computed Tomography. Splenic Diseases / etiology. Splenic Diseases / radiography. Splenic Neoplasms / complications. Splenic Neoplasms / radiography
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cooperative Behavior. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interdisciplinary Communication. Methotrexate / administration & dosage. Patient Care Team. Radiographic Image Enhancement. Rituximab. Spleen / pathology. Spleen / radiography. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Fistulas.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 2002 Aug;95(8):941-2 [12190240.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):287-90 [17098664.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):994-6 [6349784.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2460-7 [6388805.001]
  • [Cites] Saudi Med J. 2007 Dec;28(12):1898-900 [18060225.001]
  • [Cites] Ann Hematol. 2008 Apr;87(4):337-8 [17929016.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):69-70 [18386245.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Jan;101(1):76-8 [19335040.001]
  • [Cites] Rev Esp Enferm Dig. 2009 Mar;101(3):222-3 [19388805.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):e15-7 [19433680.001]
  • [Cites] Abdom Imaging. 2002 Nov-Dec;27(6):728-30 [12395264.001]
  • [Cites] Dis Colon Rectum. 1986 Aug;29(8):521-3 [3755392.001]
  • [Cites] Mayo Clin Proc. 1989 Jul;64(7):776-9 [2770360.001]
  • [Cites] Comput Med Imaging Graph. 1990 Jul-Aug;14(4):273-6 [2383867.001]
  • [Cites] J Clin Gastroenterol. 1991 Aug;13(4):478-81 [1918860.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):587-9 [8674934.001]
  • [Cites] J Thorac Imaging. 1996 Spring;11(2):150-2 [8820024.001]
  • [Cites] Am Surg. 1997 Nov;63(11):1007-10 [9358792.001]
  • [Cites] Gulf J Oncolog. 2008 Jan;(3):64-7 [20084800.001]
  • (PMID = 22791483.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  • [Other-IDs] NLM/ PMC3029570
  •  go-up   go-down


Advertisement
4. Nunes J, Tato Marinho R, Raposo J, Velosa J: [Influence of hepatitis C virus replication on splenic lymphoma with villous lymphocytes]. Acta Med Port; 2010 Sep-Oct;23(5):941-4
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of hepatitis C virus replication on splenic lymphoma with villous lymphocytes].
  • [Transliterated title] Influência da replicação do vírus da hepatite C em linfoma esplénico de células vilosas.
  • The association between hepatitis C and B-cell non-Hodgkin lymphoma (NHL) has been suggested by several studies.
  • We report the case of a 70 year-old patient with the diagnosis of chronic hepatitis C and splenic lymphoma with villous lymphocytes, who had undergone splenectomy and chemotherapy with fludarabine, with transient effectiveness.
  • He was sent to our Hepatology Clinic for the treatment of hepatitis C, and Pegylated Interferon and Ribavirin were started.
  • He had virological and hematological response (63% of villous lymphocytes in the peripheral blood at the beginning of therapy and 0% at the end).
  • With the suspension of antiviral therapy, recurrence of HCV infection and reappearance of atypical lymphocytes (24%) were observed, and Pegylated Interferon was restarted, with good response.
  • The relationship between viral and hematologic response (remission and relapse) supports the hypothesis that hepatitis C virus has an active role in the pathogenesis of splenic lymphoma with villous lymphocytes.
  • [MeSH-major] Hepacivirus / physiology. Lymphoma / virology. Splenic Neoplasms / virology. Virus Replication

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21144339.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


5. Lefrère F, Hermine O, François S, Panelatti G, Valensi F, Grosbois B, Misset JL, Varet B, Troussard X: Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma; 2000 Dec;40(1-2):113-7
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes.
  • Splenic lymphoma with villous lymphocytes (SLVL) is a B-cell chronic lymphoproliferative disorder.
  • Splenectomy and/or chlorambucil (CLB) are usually regarded as the most effective treatment in SLVL patients.
  • However, a few patients relapse and the second line therapy remains questionable.
  • Although 2-Cda has been evaluated in patients with chronic lymphoid leukemia (CLL) and hairy cell leukemia (HCL), it has been reported as the treatment of SLVL in only one case report.
  • The median duration between diagnosis and treatment was 18 months (range, 1 to 59).
  • The patients received 2-CdA (0.1 mg/kg/d) by venous infusion for 7 days with a median number of 1 cycle (range, 1 to 2) either as a first line therapy (one patient) or after a failure of other therapies (splenectomy, chemotherapy).
  • The treatment was not well tolerated with many infectious events.
  • In the limits of our study, 2-Cda does not appear to be efficient therapy for SLVL and is not well tolerated for patients in relapse after splenectomy or resistant to CLB.
  • [MeSH-major] Adenosine Triphosphate / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Cladribine / pharmacokinetics. Lymphoma, B-Cell / drug therapy. Splenic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Therapeutic Equivalency. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426611.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / cladribine triphosphate; 47M74X9YT5 / Cladribine; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


6. Moghazy KM: Gastrosplenic fistula following chemotherapy for lymphoma. Gulf J Oncolog; 2008 Jan;(3):64-7
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrosplenic fistula following chemotherapy for lymphoma.
  • Gastrosplenic fistula resulting from erosion of a primary splenic lymphoma is a very rare cause of massive upper gastrointestinal hemorrhage as compared to benign peptic ulcer disease, gastric Crohn's disease, gastric adenocarcinoma, and primary gastric and splenic lymphomas.
  • This hemorrhage can be successfully managed by splenic artery embolization, followed by splenectomy and gastric resection.
  • A 50-year-old patient developed a gastrosplenic fistula during a course of chemotherapy for differentiated histiocytic lymphoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastric Fistula / chemically induced. Lymphoma, Large B-Cell, Diffuse / drug therapy. Splenic Diseases / chemically induced
  • [MeSH-minor] Humans. Laparotomy. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084800.001).
  • [ISSN] 2078-2101
  • [Journal-full-title] The Gulf journal of oncology
  • [ISO-abbreviation] Gulf J Oncolog
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kuwait
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Singh A, Thapar V, Prabhu R, Naresh K, Joshi A, Supe A: Isolated splenic lymphoma: an elusive preoperative diagnosis. Indian J Gastroenterol; 2000 Oct-Dec;19(4):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated splenic lymphoma: an elusive preoperative diagnosis.
  • Four patients underwent splenectomy for various clinical and radiological diagnoses and were found to have primary splenic lymphoma at surgery and histology.
  • The diagnosis was classical Hodgkin's lymphoma, mixed cellularity type (one case); marginal zone B-cell non-Hodgkin's lymphoma (one case); and large B cell type non-Hodgkin's lymphoma (two cases).
  • The first two patients had multiple nodules in the spleen measuring 0.1-0.5 cm while large cell lymphomas had large nodules (largest measuring 11 cm x 7 cm x 4 cm).
  • Mean follow up of these patients was 11 months; all patients received chemotherapy.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / surgery. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Splenic Diseases / diagnosis. Splenic Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Preoperative Care. Splenectomy / methods. Splenectomy / mortality. Splenomegaly / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059187.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


8. Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, Montalban C, Matutes E, Wotherspoon A, Piris MA: Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica; 2010 Jul;95(7):1122-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.
  • BACKGROUND: Splenic diffuse red pulp small B-cell lymphoma is an uncommon B-cell lymphoma, now recognized as a provisional entity in the 2008 update of the WHO Classification.
  • DESIGN AND METHODS: We have retrospectively analyzed the disease features in a highly selected series of 17 patients diagnosed as splenic diffuse red pulp small B-cell lymphoma.
  • Splenectomy was the front-line treatment in 11 symptomatic patients; the remaining 6 received chemotherapy initially followed by splenectomy.
  • All cases showed a purely diffuse pattern of splenic infiltration by monomorphous small cells with small round nuclei and pale cytoplasm.
  • CONCLUSIONS: Our data suggest that splenic diffuse red pulp small B-cell lymphoma is a distinct entity with morphological and immunophenotypical features that differ from those of other splenic lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1999 Nov;23(11):1041-5 [10576509.001]
  • [Cites] Haematologica. 2008 May;93(5):670-9 [18367492.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1299-304 [11830479.001]
  • [Cites] Histopathology. 2002 Jan;40(1):22-30 [11903595.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2464-72 [12446449.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):41-56 [12670464.001]
  • [Cites] Lancet. 2004 Jun 5;363(9424):1869-70 [15183626.001]
  • [Cites] Leukemia. 1987 Apr;1(4):294-8 [3499540.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):211-23 [8554111.001]
  • [Cites] Histopathology. 1996 Dec;29(6):571-5 [8971565.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1583-9 [10329610.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):438-46 [17325486.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2253-60 [18042795.001]
  • [Cites] Leukemia. 2008 Mar;22(3):487-95 [18094718.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]
  • (PMID = 20220064.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2895036
  •  go-up   go-down


9. Lazaridis KN, Abraham SC, Kamath PS: Hematological malignancy manifesting as ascites. Nat Clin Pract Gastroenterol Hepatol; 2005 Feb;2(2):112-6; quiz 117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DIAGNOSIS: Primary splenic lymphoma with hepatic infiltration causing portal hypertension and ascites.
  • MANAGEMENT: Paracentesis, dietary sodium restriction and diuretics, splenectomy, splenorenal shunt and chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone).
  • [MeSH-major] Ascites / etiology. Hematologic Neoplasms / complications. Hematologic Neoplasms / diagnosis. Hypersplenism / etiology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Hypertension, Portal / etiology. Middle Aged. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265129.001).
  • [ISSN] 1743-4378
  • [Journal-full-title] Nature clinical practice. Gastroenterology & hepatology
  • [ISO-abbreviation] Nat Clin Pract Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Yasukawa M, Yamauchi H, Azuma T, Takada K, Ishimura M, Fujita S: Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes. Eur J Haematol; 2002 Aug;69(2):112-4
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dramatic efficacy of fludarabine in the treatment of an aggressive case of splenic lymphoma with villous lymphocytes.
  • Splenic lymphoma with villous lymphocytes (SLVL) is an indolent lymphoproliferative disorder of mature B lymphocytes.
  • Splenectomy is primarily recommended for treating this disease, and splenic irradiation or alkylating agents may be effective; however, frequent recurrence is observed after these therapies.
  • Although the effects of splenic irradiation and combination chemotherapy were both unsatisfactory and transient, complete remission lasting for more than 15 months was achieved after two courses of treatment with low-dose fludarabine (15 mg m(-2) daily for 3 d).
  • The present case indicates that treatment with fludarabine is effective for SLVL and recommended as the first-line therapy for elderly patients and those with an aggressive form of the disease.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Lymphoma / drug therapy. Splenic Neoplasms / drug therapy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12366716.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


11. Gotlib V, Singareddy S, Gergis U, Vakios J, Guevara E, Chadburn A, Yavorkovsky LL, Patel A, Butt A, Nayak A: Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes. Leuk Lymphoma; 2002 Jun;43(6):1337-40
Hazardous Substances Data Bank. CYANOCOBALAMIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes.
  • Splenic lymphoma with villous lymphocytes (SLVL) is an indolent hematological malignancy.
  • Organ involvement other than spleen and bone marrow is rare in SLVL.
  • Morphologic examination and immunophenotypic analyses were conducted to determine the nature of atypical lymphocytes in the peripheral blood, spleen, bone marrow and CSF.
  • The patient improved after treatment with a combination of radiation and chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Meninges / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebrospinal Fluid / cytology. Cranial Irradiation. Cyclophosphamide / administration & dosage. Dexamethasone / therapeutic use. Erythrocyte Transfusion. Humans. Lymphocytosis / etiology. Magnetic Resonance Imaging. Male. Neoplastic Stem Cells / pathology. Prednisone / administration & dosage. Vincristine / administration & dosage. Vitamin B 12 / therapeutic use. Vitamin B 12 Deficiency / complications. Vitamin B 12 Deficiency / drug therapy

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12153005.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; P6YC3EG204 / Vitamin B 12; VB0R961HZT / Prednisone; COP protocol 2
  • [Number-of-references] 9
  •  go-up   go-down


12. Zhang R, Wang D, Li Q, Sun T, Hao X: [Primary lymphoma of the spleen: clinical analysis of 23 cases]. Zhonghua Wai Ke Za Zhi; 2002 Mar;40(3):208-9
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the spleen: clinical analysis of 23 cases].
  • OBJECTIVE: To investigate the best diagnostic and therapeutic method for primary lymphoma of the spleen.
  • They accepted chemotherapy after operation.
  • B-cell type non-Hodgkin's lymphoma was noted in 21 patients and T-cell letion in 2.
  • CONCLUSIONS: The diagnosis of splenic lymphoma is dependent mainly on B-ultrasound examination and CT scanning.
  • Splenectomy combined with chemotherapy may provide optimum therapy for patients with splenic lymphoma.
  • [MeSH-major] Lymphoma / surgery. Splenic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Splenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11955418.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Lefrère F, Hermine O, Belanger C, François S, Tilly H, Lebas de La Cour JC, Valensi F, Varet B, Troussard X: Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia; 2000 Apr;14(4):573-5
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.
  • Splenic lymphoma with villous lymphocytes (SLVL) is a B cell chronic lymphoproliferative disorder.
  • Splenectomy and/or chlorambucil are usually regarded as the most effective treatment in SLVL patients.
  • However, a few patients relapse and the second-line treatment remains questionable.
  • The median duration between diagnosis and treatment was 17 months (range, 1-30).
  • The patients received FDR 25 mg/m2/day by venous infusion for 5 days with a median of four cycles of chemotherapy (range, 2-6).
  • The treatment was well tolerated.
  • FDR appears to be an efficient therapy with a favorable toxicity profile for patients in relapse after splenectomy or resistant to CLB.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Lymphoma, B-Cell / drug therapy. Splenic Neoplasms / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chlorambucil / therapeutic use. Combined Modality Therapy. Drug Evaluation. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Immunologic Factors / therapeutic use. Interferon-alpha / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Retrospective Studies. Splenectomy

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10764141.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Immunologic Factors; 0 / Interferon-alpha; 18D0SL7309 / Chlorambucil; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


14. Carr JA, Shurafa M, Velanovich V: Surgical indications in idiopathic splenomegaly. Arch Surg; 2002 Jan;137(1):64-8
Genetic Alliance. consumer health - Splenomegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: The incidence of primary lymphoma of the spleen in patients with idiopathic splenomegaly is significant.
  • Of these, 18 had idiopathic splenomegaly despite prior workup with computed tomography, peripheral smear, bone marrow biopsy, and laboratory testing.
  • INTERVENTION: All 18 patients underwent open splenectomy for diagnosis and treatment of their cytopenias.
  • MAIN OUTCOME MEASURE: Incidence of lymphoma in the pathologic specimens.
  • In all 18 patients, the surgical specimen provided a diagnosis.
  • Six patients with the benign diagnosis of hypersplenism received no further interventions, and the cytopenias resolved in all 6 cases.
  • The 7 remaining patients (39%) were diagnosed with lymphoma.
  • Five had marginal zone lymphoma, and 2 had a more aggressive B-cell lymphoma.
  • Three patients required chemotherapy, but 4 are still in remission since their splenectomies and show no evidence of active disease.
  • CONCLUSIONS: A high percentage of patients with splenomegaly of unknown etiology will have primary lymphoma of the spleen.
  • Splenectomy is both diagnostic and therapeutic and should be considered for all patients with idiopathic splenomegaly.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Splenic Neoplasms / epidemiology. Splenomegaly / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11772218.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Hamblin TJ: Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs; 2001;61(5):593-611
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It needs to be distinguished from mantle cell lymphoma and splenic marginal zone lymphoma by lymphocyte markers.
  • This group of patients have a normal life expectancy and do not require treatment beyond reassurance.
  • Progression involves an increasing white cell count, enlarging lymph nodes and spleen, anaemia and thrombocytopenia.
  • Complications of progression include autoimmune haemolytic anaemia and thrombocytopenia, immunodeficiency, and the development of a more aggressive lymphoma.
  • Intermittent chlorambucil remains the first choice treatment for the majority of patients.
  • Combination chemotherapy offers no advantage.
  • Intravenous fludarabine is probably more effective than chlorambucil, but no trial has yet shown a survival advantage for using it first rather than as a salvage treatment in patients not responding to chlorambucil.
  • It is at least 40 times as expensive as chlorambucil.
  • For patients refractory to both drugs, a variety of options are available.
  • High dose corticosteroids, high dose chlorambucil, CHOP (cyclophosphamide, prednisolone, vincristine and doxorubicin), anti-CD52, anti-CD20 and a range of experimental drugs which are being evaluated in clinical trials.
  • Younger patients should be offered the chance of treatment with curative intent, preferably in the context of a clinical trial.
  • Only time will tell whether some of these patients are cured but it seems unlikely.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 May 21;338(21):1506-14 [9593789.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1574-9 [10334546.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1885-9 [9586905.001]
  • [Cites] Am J Hematol. 1988 Nov;29(3):152-63 [3189311.001]
  • [Cites] Clin Exp Immunol. 1966 Jan;1(1):3-11 [5953036.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2107-14 [9179056.001]
  • [Cites] Br J Cancer. 1990 Jul;62(1):4-5 [2390480.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:89-91 [27463486.001]
  • [Cites] Hematol Cell Ther. 1998 Jun;40(3):113-8 [9698219.001]
  • [Cites] Br J Ophthalmol. 2000 Jan;84(1):117 [10691327.001]
  • [Cites] Acta Oncol. 1995;34(4):536-7 [7605666.001]
  • [Cites] N Engl J Med. 1990 Dec 20;323(25):1729-35 [2247105.001]
  • [Cites] N Engl J Med. 1988 Oct 6;319(14 ):902-7 [2901668.001]
  • [Cites] Am J Hematol. 1999 Feb;60(2):99-104 [9929100.001]
  • [Cites] Leuk Res. 1999 Mar;23(3):277-9 [10071081.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):359-61 [3222145.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):65-74 [9482528.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):983-8 [7707127.001]
  • [Cites] Medicine (Baltimore). 1986 Sep;65(5):339-51 [3091991.001]
  • [Cites] J Clin Oncol. 1984 Aug;2(8):881-91 [6379121.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2313-20 [9667245.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]
  • [Cites] Am J Clin Pathol. 1997 Oct;108(4):378-82 [9322589.001]
  • [Cites] Leuk Lymphoma. 1994 Sep;15(1-2):187-8 [7858499.001]
  • [Cites] Semin Hematol. 1998 Jul;35(3 Suppl 3):14-21 [9685175.001]
  • [Cites] Immunol Rev. 1998 Apr;162:247-59 [9602369.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1196-201 [2993534.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1130-5 [7630184.001]
  • [Cites] J Allergy Clin Immunol. 1996 Apr;97(4):998-1008 [8655897.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1365-74 [8695855.001]
  • [Cites] Cancer. 1977 Aug;40(2):855-64 [890666.001]
  • [Cites] Blood. 1993 Feb 1;81(3):597-601 [8094016.001]
  • [Cites] Leuk Lymphoma. 1999 Jun;34(1-2):151-7 [10350343.001]
  • [Cites] Nouv Rev Fr Hematol. 1988;30(5-6):437-42 [3065740.001]
  • [Cites] Baillieres Clin Haematol. 1993 Dec;6(4):849-66 [8038493.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1425-32 [8111709.001]
  • [Cites] Am J Hematol. 1995 Jun;49(2):135-42 [7771465.001]
  • [Cites] Clin Lab Haematol. 1997 Jun;19(2):151-2 [9218157.001]
  • [Cites] N Engl J Med. 1993 Mar 18;328(11):813-4 [8094890.001]
  • [Cites] Ann Oncol. 1999 Mar;10(3):362-3 [10355587.001]
  • [Cites] Ann Hematol. 1997 Nov-Dec;75(5-6):227-30 [9433380.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):46-50 [9020373.001]
  • [Cites] Arch Intern Med. 1996 Jan 22;156(2):177-88 [8546551.001]
  • [Cites] Am J Med. 1990 Sep;89(3):388-90 [1697447.001]
  • [Cites] Cancer. 1973 Mar;31(3):502-8 [4693581.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1104-8 [7850708.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):509-14 [8882965.001]
  • [Cites] Br J Haematol. 1981 Apr;47(4):529-37 [7213576.001]
  • [Cites] Leukemia. 1997 Jan;11(1):170 [9001435.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1969-80 [9885918.001]
  • [Cites] Br J Haematol. 1986 Jun;63(2):377-87 [3487341.001]
  • [Cites] Eur J Haematol. 1997 Feb;58(2):109-13 [9111592.001]
  • [Cites] Am J Hematol. 1999 Dec;62(4):242-6 [10589081.001]
  • [Cites] Tumori. 1995 Nov-Dec;81(6):419-23 [8804467.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4259-64 [8943862.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2431-48 [7666104.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1569-73 [1679357.001]
  • [Cites] Leuk Res. 2000 Jan;24(1):27-31 [10634642.001]
  • [Cites] Br J Haematol. 1986 Mar;62(3):567-75 [3954968.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):836-7 [10469479.001]
  • [Cites] Ann Pharmacother. 1992 Jul-Aug;26(7-8):939-47 [1504408.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] J Clin Oncol. 1989 Apr;7(4):433-8 [2784491.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):140-4 [2112977.001]
  • [Cites] Ann Oncol. 1995 Mar;6(3):300-1 [7612497.001]
  • [Cites] J Natl Cancer Inst. 1990 Sep 5;82(17):1416-20 [2388293.001]
  • [Cites] N Engl J Med. 1991 Jul 11;325(2):81-6 [1904989.001]
  • [Cites] N Engl J Med. 1990 Sep 13;323(11):720-4 [2201915.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3209-10 [9738600.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):649-52 [7819085.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):826-8 [8536738.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1112-3 [9734670.001]
  • [Cites] Sangre (Barc). 1997 Jun;42(3):254-6 [9381277.001]
  • [Cites] N Engl J Med. 1992 Oct 8;327(15):1056-61 [1355853.001]
  • [Cites] Novartis Found Symp. 1998;215:200-11; discussion 211-30 [9760581.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Nephrol Dial Transplant. 1996 Nov;11(11):2306-8 [8941597.001]
  • [Cites] Lancet. 1993 Aug 28;342(8870):555 [8102691.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):730-1 [8664199.001]
  • [Cites] Semin Oncol. 1998 Feb;25(1):80-97 [9482530.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):341-4 [8547072.001]
  • [Cites] Haematologica. 1996 Mar-Apr;81(2):121-6 [8641639.001]
  • [Cites] Concepts Immunopathol. 1987;4:24-41 [2885092.001]
  • [Cites] Br J Haematol. 1998 Mar;100(4):677-9 [9531333.001]
  • [Cites] Ann Oncol. 1995 May;6(5):421-33 [7669706.001]
  • [Cites] Am J Pathol. 1928 Jul;4(4):285-292.7 [19969796.001]
  • [Cites] J Clin Oncol. 1993 Apr;11(4):679-89 [8097528.001]
  • [Cites] Baillieres Clin Haematol. 1987 Jun;1(2):449-91 [3322445.001]
  • [Cites] Acta Haematol. 1995;93(2-4):73-9 [7543720.001]
  • [Cites] J Clin Pathol. 1995 Feb;48(2):181-2 [7745121.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):287-96 [9670041.001]
  • [Cites] Br Med J. 1973 Oct 6;4(5883):23-4 [4585418.001]
  • [Cites] Leuk Lymphoma. 1991;5 Suppl 1:133-8 [27463495.001]
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):391-8 [9684936.001]
  • [Cites] Am J Hematol. 1995 Apr;48(4):293 [7717386.001]
  • [Cites] Leukemia. 1999 Apr;13(4):518-23 [10214856.001]
  • [Cites] Am J Hematol. 1990 Sep;35(1):32-6 [2202205.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):238-9 [1457584.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):861-8 [10340906.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):748-58 [8151318.001]
  • [Cites] Ann Intern Med. 1988 May;108(5):733-43 [3282467.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):458-65 [9053466.001]
  • [Cites] Br J Haematol. 1996 Feb;92(2):382-8 [8603004.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1144-50 [9067285.001]
  • [Cites] Br Med J. 1974 Sep 14;3(5932):655-7 [4279123.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] Ann Hematol. 2000 Jan;79(1):43-5 [10663621.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2455-7 [10787241.001]
  • [Cites] Ann Intern Med. 1996 Feb 1;124(3):311-5 [8554226.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):833-4 [1697401.001]
  • [Cites] Br J Cancer. 1984 May;49(5):547-57 [6722005.001]
  • [Cites] Leuk Lymphoma. 1993 Sep;11(1-2):63-8 [8220155.001]
  • [Cites] N Engl J Med. 1994 Feb 3;330(5):319-22 [7904047.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1567-74 [9193354.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):117-22 [10052715.001]
  • [Cites] Ann Oncol. 1992 Feb;3(2):171-2 [1606091.001]
  • (PMID = 11368285.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 156
  •  go-up   go-down


16. Eloubeidi MA, Varadarajulu S, Eltoum I, Jhala D, Chhieng DC, Jhala NC: Transgastric endoscopic ultrasound-guided fine-needle aspiration biopsy and flow cytometry of suspected lymphoma of the spleen. Endoscopy; 2006 Jun;38(6):617-20
MedlinePlus Health Information. consumer health - Spleen Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transgastric endoscopic ultrasound-guided fine-needle aspiration biopsy and flow cytometry of suspected lymphoma of the spleen.
  • BACKGROUND AND STUDY AIMS: Masses in the spleen can be sampled by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) but the diagnosis of lymphoma using EUS-FNA and flow cytometry has not been reported.
  • We report our experience with transgastric EUS-FNA and flow cytometry in the investigation of patients with suspected lymphoma of the spleen.
  • PATIENTS AND METHODS: All patients with splenic lesions that had been detected by computed tomography and who were referred for transgastric EUS-FNA over a 3-year period were enrolled in this study.
  • The tissue obtained by EUS-FNA was evaluated by flow cytometry in all patients.
  • RESULTS: Six patients with splenic masses were enrolled (four men, two women; median age 58.5 years, range 41 - 82 years).
  • EUS-FNA was performed successfully in all patients and the tissue obtained was evaluated by flow cytometry.
  • Two patients were diagnosed with lymphoma; no pathology was identified in the other four patients.
  • Lymphoma of the spleen appeared as sharply demarcated echo-poor lesions; benign lesions appeared echo-rich in comparison with the surrounding splenic tissue.
  • The two patients who were diagnosed with lymphoma underwent chemotherapy.
  • Of the four patients in whom no pathology was identified, one patient subsequently underwent splenectomy for evaluation of persistent abdominal pain and was diagnosed with lymphoma; the three other patients had true-negative disease on the evidence of long-term follow-up (mean 8 months; range 6 - 12 months).
  • No complications related to the EUS-FNA procedure were encountered in any patient.
  • CONCLUSIONS: EUS-FNA of spleen masses is a safe technique that aids in the diagnosis of lymphoma when used in conjunction with flow cytometry.
  • [MeSH-major] Endoscopy, Gastrointestinal. Endosonography. Flow Cytometry / methods. Lymphoma / pathology. Splenic Diseases / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Reproducibility of Results. Retrospective Studies. Stomach

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685607.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Koch CA, Pacak K: Abnormal ACTH-stimulation test in a patient with AIDS: adrenal insufficiency or toxoplasmosis? Endocr Regul; 2001 Jun;35(2):91-3
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On further evaluation, he was found to have recurrent Non-Hodgkin lymphoma (spleen) and intracranial toxoplasmosis, perhaps imitating or aggravating symptoms suggestive of adrenal insufficiency (AI).
  • We diagnosed secondary AI due to megace treatment and tapered this medication under simultaneous hydrocortisone replacement therapy.
  • We conclude that patients with AIDS on megace therapy should receive special attention in regards to the potential development of AI, especially in stress situations such as infections or pain.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Adrenal Insufficiency / diagnosis. Adrenocorticotropic Hormone. Toxoplasmosis, Cerebral / diagnosis
  • [MeSH-minor] Adult. Anti-Infective Agents / therapeutic use. Diagnosis, Differential. Humans. Male. Megestrol Acetate / antagonists & inhibitors. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11563937.001).
  • [ISSN] 1210-0668
  • [Journal-full-title] Endocrine regulations
  • [ISO-abbreviation] Endocr Regul
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 9002-60-2 / Adrenocorticotropic Hormone; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


18. Gordon MM, Lucie N, Porter D: Acquired C1q deficiency caused by monoclonal paraproteinaemia. Lupus; 2000;9(1):68-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some patients with acquired C1 inhibitor deficiency are found to have an underlying malignancy, most commonly lymphoma.
  • We report a case of a 40-year-old man presenting with a lupus-like illness with acquired C1q deficiency secondary to a monoclonal paraprotein in the presence of splenic lymphoma with villous lymphocytes.
  • There was no improvement in his clinical condition following combination chemotherapy.
  • [MeSH-major] Complement C1q / deficiency. Lymphoma / complications. Paraproteinemias / complications. Splenic Neoplasms / complications
  • [MeSH-minor] Adult. Complement C3 / analysis. Complement C4 / analysis. Glucocorticoids / therapeutic use. Humans. Male. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - C1q deficiency.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10713650.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Complement C3; 0 / Complement C4; 0 / Glucocorticoids; 80295-33-6 / Complement C1q; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


19. Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, Podevin P, Bouscary D, Sogni P, Blanche P, Dreyfus F: Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia; 2004 Oct;18(10):1711-6
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.
  • A link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies.
  • Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection.
  • In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepacivirus / pathogenicity. Hepatitis C / drug therapy. Lymphoma, B-Cell / virology
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Prospective Studies. Retrospective Studies. Ribavirin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2004 Oct;18(10):1572-5 [15284857.001]
  • (PMID = 15284859.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 49717AWG6K / Ribavirin
  •  go-up   go-down


20. Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M: Marginal zone-related neoplasms of splenic and nodal origin. Haematologica; 2003 Jan;88(1):80-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone-related neoplasms of splenic and nodal origin.
  • BACKGROUND: The marginal zone is an anatomically distinct B-cell compartment of lymphoid tissue with an abundant antigenic influx.
  • Among marginal zone-derived lymphomas the WHO classification listed, in addition to extranodal marginal zone B-cell lymphoma of MALT type, two other marginal zone B-cell neoplasms: splenic marginal zone B-cell lymphoma (+/- villous lymphocytes) and nodal marginal zone B-cell lymphoma (+/- monocytoid B cells).
  • Treatment options are heterogeneous, including a watch-and-wait policy, surgery with or without chemotherapy, purine analogs, and interferon.
  • STATE OF THE ART: Splenic and nodal marginal zone lymphomas are typical low-grade lymphomas with an indolent course.
  • The role played by hepatitis C virus (HCV) in marginal zone lymphomas is not fully elucidated, but there is demonstration that eradication of HCV infection in splenic lymphoma with villous lymphocytes causes regression of the lymphoma.
  • The optimal treatment has not yet been identified.
  • Retrospective series, however, show that splenectomy is a good option if symptoms from the presence of spleen enlargement or cytopenias need to be treated.
  • The optimal therapeutic approach and the role of new treatments need to be assessed in prospective clinical trials.
  • [MeSH-major] Lymphoma, B-Cell / pathology
  • [MeSH-minor] Humans. Lymph Nodes / pathology. Prognosis. Spleen / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12551831.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 95
  •  go-up   go-down


21. Bronzino P, Abbo L, Bagnasco F, Barisone P, Dezzani C, Genovese AM, Iannucci P, Ippoliti M, Sacchi M, Aimo I: [Splenic marginal zone lymphoma: case report and review of the literature]. G Chir; 2005 Nov-Dec;26(11-12):419-21
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic marginal zone lymphoma: case report and review of the literature].
  • [Transliterated title] Linfoma splenico della marginale: descrizione di un caso clinico e revisione della letteratura.
  • Splenic marginal zone lymphomas are rare tumors which take origin from the B cells.
  • Computed tomography demonstrated splenomegaly with an area of low density in the spleen.
  • Only by laparotomy and splenectomy the correct diagnosis was possible.
  • Because of the indolent course of this kind of lymphomas, splenectomy is the main treatment for patients with abdominal pain, splenomegaly and cytopenia.
  • If there is no pain and no cytopenia, the treatment can be only wait and see.
  • Only in case of progression of disease chemotherapy can be employed.
  • [MeSH-major] Lymphoma. Splenic Neoplasms
  • [MeSH-minor] Abdominal Pain / etiology. Aged. Diagnosis, Differential. Disease Progression. Female. Humans. Immunohistochemistry. Laparotomy. Prognosis. Radiography, Abdominal. Spleen / pathology. Splenectomy. Splenomegaly / etiology. Splenomegaly / pathology. Splenomegaly / radiography. Splenomegaly / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472419.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


22. Harada S, Kalla H, Balasubramanian M, Brodsky I, Gladstone D, Hou JS: Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen. Ann Diagn Pathol; 2008 Jun;12(3):212-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classical Hodgkin lymphoma concurrently evolving in a patient with marginal zone B-cell lymphoma of the spleen.
  • Combination of the splenic marginal zone B-cell lymphoma (SMZL) and classical Hodgkin lymphoma (cHL) is extremely rare.
  • After the chemotherapy, the patient achieved a clinical/radiologic remission, whereas cHL was detected in liver and bone marrow subsequently.
  • The case indicates that both components of lymphoma can present concurrently as a composite form of lymphoma and both need to be treated adequately.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / analysis. B-Lymphocytes / chemistry. B-Lymphocytes / pathology. Combined Modality Therapy. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Lymphatic Diseases. Male. Middle Aged. Reed-Sternberg Cells / pathology. Remission Induction. Splenomegaly

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486899.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


23. Hermine O, Lefrère F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, Delmas B, Valensi F, Cacoub P, Brechot C, Varet B, Troussard X: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med; 2002 Jul 11;347(2):89-94
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.
  • BACKGROUND: Some epidemiologic studies suggest a link between hepatitis C virus (HCV) infection and some B-cell non-Hodgkin's lymphomas.
  • We undertook this study after a patient with splenic lymphoma with villous lymphocytes had a hematologic response after antiviral treatment of HCV infection.
  • METHODS: Nine patients who had splenic lymphoma with villous lymphocytes and HCV infection were treated with interferon alfa-2b (3 million IU three times per week) alone or in combination with ribavirin (1000 to 1200 mg per day).
  • The outcomes were compared with those of six similarly treated patients with splenic lymphoma with villous lymphocytes who tested negative for HCV infection.
  • In contrast, none of the six HCV-negative patients had a response to interferon therapy.
  • CONCLUSIONS: In patients with splenic lymphoma with villous lymphocytes who are infected with HCV, treatment with interferon can lead to regression of the lymphoma.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepacivirus / pathogenicity. Hepatitis C / drug therapy. Interferon-alpha / therapeutic use. Lymphoma, B-Cell / virology. Splenic Neoplasms / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2002 Jul 11;347(2):78-9 [12110734.001]
  • [CommentIn] N Engl J Med. 2002 Dec 26;347(26):2168-70; author reply 2168-70 [12501232.001]
  • [CommentIn] N Engl J Med. 2002 Dec 26;347(26):2168-70; author reply 2168-70 [12501854.001]
  • [CommentIn] N Engl J Med. 2003 Nov 20;349(21):2078-9 [14627800.001]
  • [CommentIn] Gastroenterology. 2003 Apr;124(4):1157-8 [15534980.001]
  • [CommentIn] N Engl J Med. 2002 Dec 26;347(26):2168-70; author reply 2168-70 [12501855.001]
  • (PMID = 12110736.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral
  •  go-up   go-down


24. Iriyama N, Horikoshi A, Hatta Y, Kobayashi Y, Sawada S, Takeuchi J: Localized, splenic, diffuse large B-cell lymphoma presenting with hypersplenism: risk and benefit of splenectomy. Intern Med; 2010;49(11):1027-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized, splenic, diffuse large B-cell lymphoma presenting with hypersplenism: risk and benefit of splenectomy.
  • Herein we report a case of a localized, massive, diffuse large B-cell splenic lymphoma diagnosed by splenectomy.
  • Enhanced computed tomography scanning showed an irregularly enhanced effect in the spleen suggesting a diffuse splenic tumor.
  • The resected spleen weighed 3,500 g.
  • After the operation, the patient recovered from the pancytopenia and pathology diagnosed diffuse large B-cell lymphoma.
  • Standard CHOP plus rituximab chemotherapy was given.
  • [MeSH-major] Hypersplenism / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Splenectomy / adverse effects. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519821.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Han SM, Teng CL, Hwang GY, Chou G, Tsai CA: Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture. J Chin Med Assoc; 2008 Apr;71(4):210-3
Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic lymphoma associated with hemophagocytic lymphohistiocytosis complicated with splenic rupture.
  • Primary splenic lymphoma (PSL) is a rare disease with ambiguous definition, comprising less than 1% of non-Hodgkin's lymphoma.
  • Refusing diagnostic splenectomy, he received chemotherapy.
  • Spontaneous splenic rupture occurred after chemotherapy.
  • He received another 5 courses of chemotherapy with the R-CNOP regimen (rituximab, cyclophosphamide, mitoxantrone, vincristine, prednisolone).
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / complications. Lymphoma, Large B-Cell, Diffuse / complications. Splenic Neoplasms / complications. Splenic Rupture / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436505.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


26. Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, Seymour JF: Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. Clin Lymphoma; 2005 Mar;5(4):294-7
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
  • The WM1 study is a prospective randomized open-label study that includes patients with previously untreated Waldenstrom's macroglobulinemia (WM), splenic lymphoma with villous lymphocytes (SLVL), and nonimmunoglobulin (Ig) M lymphoplasmacytic lymphoma (LPL) who have an indication for treatment.
  • Primary endpoints are response to therapy and duration of response; secondary endpoints are improvement in hematologic parameters, toxicity of therapy, quality of life, and survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Chlorambucil / therapeutic use. Lymphoma / drug therapy. Splenic Neoplasms / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794869.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


27. Grosskreutz C, Troy K, Cuttner J: Primary splenic lymphoma: report of 10 cases using the REAL classification. Cancer Invest; 2002;20(5-6):749-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic lymphoma: report of 10 cases using the REAL classification.
  • Primary splenic lymphoma (PSL) is rare with a reported incidence of less than 1%.
  • Our objective was to evaluate staging (using the Ahmann and Kehoe criteria), prognosis using the International Prognostic Index (IPI), and pathology using the Revised European-American Lymphoma Classification (REAL) classification.
  • Eight of the 10 patients had diffuse large cell lymphoma (DLCL).
  • Lymph node involvement beyond the splenic hilum seen by imaging studies represents an advanced non-Hodgkin's lymphoma and should be included no longer in the staging of PSL.
  • Eight of the nine patients received chemotherapy following splenectomy.
  • Splenectomy followed by combination chemotherapy, results in excellent long-term survival in PSL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Splenectomy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12197231.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Elmahy H, Hawley I, Beard J: Composite splenic marginal zone lymphoma and classic Hodgkin lymphoma -- an unusual combination. Int J Lab Hematol; 2007 Dec;29(6):461-3
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite splenic marginal zone lymphoma and classic Hodgkin lymphoma -- an unusual combination.
  • The simultaneous occurrence of Hodgkin lymphoma with a variety of B-cell Non-Hodgkin lymphomas (composite lymphoma) has been described.
  • We report the first case of composite Hodgkin lymphoma and splenic marginal zone lymphoma occurring simultaneously in the same lymph node of a 64-year-old man who presented with cervical and axillary lymphadenopathy and massive splenomegaly.
  • However, cervical lymph node biopsy showed classic Hodgkin lymphoma.
  • His splenomegaly showed only a partial response to six cycles of ABVD chemotherapy so he underwent splenectomy with biopsy of remaining nodes.
  • Histology of the spleen and nodes showed splenic marginal zone lymphoma.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasms, Second Primary / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy. Bleomycin / administration & dosage. Bone Marrow Cells / pathology. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Humans. Lymph Nodes / pathology. Lymphocytes / pathology. Lymphocytosis / pathology. Lymphocytosis / therapy. Male. Middle Aged. Splenectomy. Splenomegaly / pathology. Splenomegaly / therapy. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988302.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


31. Puli SR, Farrell JS, Alpert MA: Isolated gastric varices occurring 5 years after chemotherapy for splenic lymphoma. Ann Intern Med; 2004 Jun 15;140(12):1062-3
MedlinePlus Health Information. consumer health - Vascular Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated gastric varices occurring 5 years after chemotherapy for splenic lymphoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Esophageal and Gastric Varices / etiology. Lymphoma / drug therapy. Splenic Neoplasms / drug therapy. Splenic Vein. Vascular Diseases / complications
  • [MeSH-minor] Aged. Humans. Inflammation / complications. Male. Time Factors

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197032.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Kanbay M, Selcuk H, Gur G, Dagli N, Karakus S, Yilmaz U: Response to peginterferon treatment in hepatitis C virus-associated splenic lymphoma with villous lymphocytes. Am J Hematol; 2006 Apr;81(4):304-5
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to peginterferon treatment in hepatitis C virus-associated splenic lymphoma with villous lymphocytes.
  • [MeSH-major] Antiviral Agents / administration & dosage. Hepatitis C / drug therapy. Interferon-alpha / administration & dosage. Lymphoma, B-Cell / drug therapy. Splenic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550519.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


33. Lefrère F, Lévy V, François S, Delarue R, Ifrah N, Tilly H, Valensi F, Troussard X, Varet B, Hermine O: Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update. Leukemia; 2004 Nov;18(11):1924-5
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphocytes / pathology. Lymphoma / drug therapy. Splenic Neoplasms / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15385943.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


34. Mazzaro C, Little D, Pozzato G: Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med; 2002 Dec 26;347(26):2168-70; author reply 2168-70
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of splenic lymphoma after treatment of hepatitis C virus infection.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepacivirus / genetics. Hepatitis C / drug therapy. Lymphoma, B-Cell / virology. Lymphoma, Non-Hodgkin / virology. Splenic Neoplasms / virology
  • [MeSH-minor] Cryoglobulinemia / complications. Genotype. Humans. Interferons / therapeutic use. RNA, Viral / analysis. Remission Induction

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • (PMID = 12501232.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / RNA, Viral; 9008-11-1 / Interferons
  •  go-up   go-down


35. Agnello V, Mecucci C, Casato M: Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med; 2002 Dec 26;347(26):2168-70; author reply 2168-70
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of splenic lymphoma after treatment of hepatitis C virus infection.
  • [MeSH-major] Cryoglobulinemia / complications. Hepatitis C / drug therapy. Lymphoma, B-Cell / complications. Splenic Neoplasms / complications
  • [MeSH-minor] Antiviral Agents / therapeutic use. B-Lymphocytes / classification. Clone Cells. Cryoglobulins / classification. Cyclin D1 / metabolism. Hepacivirus. Humans

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • (PMID = 12501854.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Cryoglobulins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


36. Rocco S, Improta S, Sagristani M, Quirino AA, Nitrato Izzo G, Russolillo S, Polistina MT, Mastrullo L: Severe T-mediated bone marrow aplasia in a patient with splenic lymphoma with villous lymphocytes (SLVL) previously treated with fludarabine regimen. Haematologica; 2004 Jun;89(6 Suppl):ECR19
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe T-mediated bone marrow aplasia in a patient with splenic lymphoma with villous lymphocytes (SLVL) previously treated with fludarabine regimen.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Marrow Diseases / chemically induced. Lymphoma, B-Cell / drug therapy. Splenic Neoplasms / drug therapy. T-Lymphocytes / pathology. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15194555.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


37. Emens LA, Sulkowski MS: Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med; 2002 Dec 26;347(26):2168-70; author reply 2168-70
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of splenic lymphoma after treatment of hepatitis C virus infection.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis C, Chronic / drug therapy. Lymphoma, B-Cell / virology. Splenic Neoplasms / virology
  • [MeSH-minor] Cryoglobulinemia / complications. Hepacivirus / genetics. Humans. Interferon-alpha / therapeutic use. RNA, Viral / analysis. Ribavirin / therapeutic use

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • (PMID = 12501855.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / RNA, Viral; 49717AWG6K / Ribavirin
  •  go-up   go-down


38. Stasolla A, Kharrub Z, Colaiacomo MC, Cirelli G, Cirelli A, Marini M: Isolated non-Hodgkin's lymphoma of the spleen: CT findings in an AIDS patient treated with highly active antiretroviral therapy. Radiol Med; 2002 Jul-Aug;104(1-2):111-4
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated non-Hodgkin's lymphoma of the spleen: CT findings in an AIDS patient treated with highly active antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / radiography. Splenic Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Biopsy. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Time Factors. Tomography, Spiral Computed






Advertisement